ProfileGDS5678 / 1431847_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 8% 8% 8% 7% 7% 8% 8% 8% 7% 7% 8% 8% 8% 8% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.202178
GSM967853U87-EV human glioblastoma xenograft - Control 22.176898
GSM967854U87-EV human glioblastoma xenograft - Control 32.180518
GSM967855U87-EV human glioblastoma xenograft - Control 42.127827
GSM967856U87-EV human glioblastoma xenograft - Control 52.121557
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.23148
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.197958
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.157588
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.147267
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.16237
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.165468
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.162818
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.173458
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.168038